EMA and NICE Appraisal Processes for Cancer Drugs: Current Status and Uncertainties

Rumona Dickson (Corresponding Author), Angela Boland, Rui Duarte, Eleanor Kotas, Nerys Woolacott, Robert Hodgson, Rob Riemsma, Sabine Grimm, Bram Ramaekers, Manuela Joore, Nasuh Büyükkaramikli, Eva Kaltenthaler, Matt Stevenson, Abdullah Pandor, Steve Edwards, Martin Hoyle, Jonathan Shepherd, Xavier Armoiry, Miriam Brazzelli

Research output: Contribution to journalArticlepeer-review

12 Citations (Scopus)
8 Downloads (Pure)
Original languageEnglish
Pages (from-to)429-432
Number of pages4
JournalApplied Health Economics and Health Policy
Issue number4
Early online date28 May 2018
Publication statusPublished - Aug 2018

Bibliographical note

The Evidence Review Group members that contributed to this editorial are funded by the UK NIHR HTA Programme. The views and opinions expressed are those of the authors and do not necessarily reflect those of the UK Department of Health and the NIHR.

Cite this